Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 4/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ATG7 | O95352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22579701 | 0.87 | HRH4 (0.31) | TNK2HRH4HRH3 | |
| SCHEMBL23823026 | 0.87 | TNK2 (0.34) | TNK2HSPA5HRH4HRH3TAAR1 | |
| SCHEMBL12243148 | 0.87 | TNK2 (0.34) | TNK2HSPA5HRH4HRH3TAAR1 | |
| SCHEMBL18490453 | 0.84 | PDE2A (0.38) | TNK2HSPA5PDE2AATG7 | |
| SCHEMBL24539016 | 0.84 | PDE2A (0.38) | TNK2HSPA5PDE2AATG7 | |
| SCHEMBL21759078 | 0.84 | PDE2A (0.38) | TNK2HSPA5PDE2AATG7 | |
| SCHEMBL30592031 | 0.84 | PDE2A (0.38) | TNK2HSPA5PDE2AATG7 | |
| SCHEMBL20434838 | 0.84 | PDE2A (0.38) | TNK2HSPA5PDE2AATG7 | |
| SCHEMBL12835934 | 0.80 | HRH4 (0.33) | HRH4HRH3PDE4DLMNA | |
| SCHEMBL12243125 | 0.80 | HRH4 (0.33) | HRH4HRH3PDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | TNK2 594/4885HSPA5 4513/4885HRH4 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.